FIGURE 1.
Details of patients' response to ADA at week 12 according to the CDEIS scores. At baseline, patients were divided into four groups. They were quiescent CD (CDEIS <3) (A), mildly active CD (3 ≤ CDEIS < 9) (B), moderately active CD (9 ≤ CDEIS < 12) (C), and severely active CD (CDEIS ≥12) (D). ADA, adalimumab; CDEIS, Crohn’s Disease Endoscopic Index of Severity; ns, not significant; ***p < 0.001.